TENAX THERAPEUTICS, INC.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
TENX$1.69-5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Amounts in thousands, except share data)
| Preferred Stock · Common Stock | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Shares · Amount · Number of Shares · Amount · Additional paid-in capital · Accumulated deficit · Total stockholders' equity | |||||||||||||
| Balance at December 31, 2022 | 210 | $ | - | 28,647 | $ | - | $291,035 | $(289,542) | $1,493 | ||||
| Public offering sale of common stock and warrants, net of offering costs of $1,473 | 86,994 | - | 14,125 | 14,125 | |||||||||
| Exercise of pre-funded warrants for cash | 18,076 | - | 1 | 1 | |||||||||
| Exercise of pre-funded warrants, cashless | 3,259 | - | - | - | |||||||||
| Exercise of warrants, cashless | 161,131 | - | - | - | |||||||||
| Stock split and fractional shares issued | 174 | - | (1) | (1) | |||||||||
| Stock-based compensation expense | 191 | 191 | |||||||||||
| Net loss | (7,711) | (7,711) | |||||||||||
| Balance at December 31, 2023 | 210 | $ | - | 298,281 | $ | - | $305,351 | $(297,253) | $8,098 | ||||
| Public offering sale of common stock, warrants, and prefunded warrants, net of offering costs of $8,416 | 1,871,921 | - | 100,303 | 100,303 | |||||||||
| Exercise of pre-funded warrants for cash | 973,240 | - | 1 | 1 | |||||||||
| Exercise of pre-funded warrants, cashless | 205,467 | - | - | - | |||||||||
| Exercise of warrants | 12,000 | - | 68 | 68 | |||||||||
| Stock split and fractional shares issued | 59,997 | - | - | - | |||||||||
| Stock-based compensation expense | 1,125 | 1,125 | |||||||||||
| Net loss | (17,602) | (17,602) | |||||||||||
| Balance at December 31, 2024 | 210 | $ | - | 3,420,906 | $ | - | $406,848 | $(314,855) | $91,993 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.